Biocorrx Inc. (BICX) — 10-Q Filings
All 10-Q filings from Biocorrx Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
BioCorRx Revenue Soars Post-Lucemyra Acquisition, Net Loss Widens
— Nov 14, 2025 Risk: high
BioCorRx Inc. reported a significant increase in revenue to $948,362 for the nine months ended September 30, 2025, compared to $7,665 in the same period of 2024 -
BioCorRx Revenue Soars 40x on Lucemyra Acquisition, Net Loss Narrows
— Aug 14, 2025 Risk: high
BioCorRx Inc. reported a significant increase in revenue for the six months ended June 30, 2025, reaching $313,137, a substantial rise from $7,665 in the same p -
BioCorRx Q1 Revenue Plummets, Assets Stand at $2.2M
— May 15, 2025 Risk: high
BioCorRx Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $61,638 in revenue for the three months ended March 31, 2025, a signific -
BioCorRx Inc. Reports Q3 2024 with Key Subsequent Events
— Nov 14, 2024 Risk: medium
BioCorRx Inc. filed its Q3 2024 10-Q report on November 14, 2024, covering the period ending September 30, 2024. The company reported significant subsequent eve -
BioCorRx Inc. Q2 2024 10-Q Filed
— Aug 13, 2024 Risk: medium
BioCorRx Inc. filed a 10-Q for the period ending June 30, 2024. The company reported total assets of $8.67 million and total liabilities of $80,000. Revenue for -
BioCorRx Inc. Files 10-Q for Period Ending March 31, 2024
— May 15, 2024 Risk: low
BioCorRx Inc. (BICX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. BioCorRx Inc. reported financial results for the quarter ended March 31, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX